Nanologica launches $11.2M rights issue to fund North America, Europe push
What's the deal? Swedish nanotechnology firm NanologicaDealroom has a profile for this one. Try Dealroom → has resolved on a partially guaranteed rights issue of about US$13.4M (roughly $11.2 million), with an oversubscription option for an additional US$1.21M. The post-IPO equity raise gives existing shareholders preferential rights at US$0.2 per unit.
Who's backing it? Principal owner Flerie InvestDealroom has a profile for this one. Try Dealroom → has committed US$2.42M and Ardena GentDealroom has a profile for this one. Try Dealroom → about US$870.3K. Chairman Thomas Eldered — via T&M Participation — Ardena, and partner Sterling Pharma SolutionsDealroom has a profile for this one. Try Dealroom → have made top guarantee commitments totalling about US$4.96M.
How secure is it? Subscription commitments, guarantee commitments, and a guarantee intention cover about US$10.4M — some 77.6% of the issue. Bergs Securities has signalled a bottom guarantee of roughly US$2.05M, backed by sub-guarantee agreements with an investor consortium.
Why now? The raise underpins a strategy shift to accelerate commercial growth, with increased focus on North America and Europe. It lands alongside a management change announced the same day.
New leadership: Mark Quick takes over as the group's chief executive officer, while Andreas Bhagwani — who previously led the company — moves to general manager of Nanologica's purification and separation business.
The signal: The round sits in the smaller tier of disclosed deals, ranking around the 2.6th percentile by size. For a listed microcap, tapping existing shareholders through a guaranteed rights issue is a pragmatic way to fund a commercial expansion without seeking fresh outside capital.
Read more: view.news.eu.nasdaq.com
Image credit: Generated with Gemini
